Oka Satoko, Ono Kazuo, Nohgawa Masaharu
Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
Division of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
J Clin Pharm Ther. 2018 Dec;43(6):914-917. doi: 10.1111/jcpt.12740. Epub 2018 Jul 4.
Optimal strategies for treating patients with very advanced relapsed and refractory multiple myeloma (RRMM) have not been clarified.
A 80-year-old patient with RRMM experienced extramedullary relapse following treatment with bortezomib, lenalidomide and pomalidomide. However, he achieved very good partial remission after retreatment with lenalidomide.
This report illustrates that patients with very advanced RRMM can still respond to prior therapy even after being exposed and refractory to several agents. Considering the depth or duration of response to prior treatment, "retreatment" may improve the outcome of frail RRMM.
治疗极晚期复发难治性多发性骨髓瘤（RRMM）患者的最佳策略尚未明确。
一名80岁的RRMM患者在接受硼替佐米、来那度胺和泊马度胺治疗后发生髓外复发。然而，他在接受来那度胺再治疗后获得了非常好的部分缓解。
本报告表明，极晚期RRMM患者即使在接触过多种药物并对其耐药后，仍可能对先前的治疗有反应。考虑到对先前治疗的反应深度或持续时间，“再治疗”可能改善体弱RRMM患者的预后。
